Clinical Trial Update: Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Lu-177 PSMA-directed endoradiotherapy for metastatic castration-resistant prostate cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-directed endoradiotherapy (Lutetium-177-PSMA)

Snippet

Sponsor: Endocyte | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-03-24